Subscribers

Trendlines says its most valuable portfolio company is Stimatix

Stimatix sold its assets in Nov 2014 to a B Braun subsidiary; Trendlines' current holding of 28.2% valued at US$42.6m

Singapore

CATALIST-LISTED The Trendlines Group - an Israel and Singapore-based incubator of medtech and agritech startups - has disclosed that an asset it described as its "Most Valuable Portfolio Company" is Stimatix GI.

In a statement on Monday, Trendlines said that Stimatix, which develops medical products to aid patients with intestinal blockage, sold its assets in November 2014 to a subsidiary of German medical device company B Braun Group. B Braun will market Stimatix's ostomy products internationally...

KEYWORDS IN THIS ARTICLE

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes